Page last updated: 2024-09-04

docetaxel anhydrous and vadimezan

docetaxel anhydrous has been researched along with vadimezan in 3 studies

Compound Research Comparison

Studies (docetaxel anhydrous)	Trials (docetaxel anhydrous)	Recent Studies (post-2010) (docetaxel anhydrous)	Studies (vadimezan)	Trials (vadimezan)	Recent Studies (post-2010) (vadimezan)
12,110	3,216	6,920	272	16	101

Protein Interaction Comparison

Protein	Taxonomy	docetaxel anhydrous (IC50)	vadimezan (IC50)
Stimulator of interferon genes protein	Mus musculus (house mouse)		1.2

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
McKeage, MJ	1
Clingan, P; Dreicer, R; Goel, S; Leach, J; Mainwaring, PN; Pili, R; Rosenthal, MA; Srinivas, S; Van Hazel, G; Wong, S	1
Daga, H; Hida, T; Horio, Y; Ishikawa, S; Kobayashi, K; Shimizu, J; Takeda, K; Tokunaga, S	1

Reviews

1 review(s) available for docetaxel anhydrous and vadimezan

Article	Year
The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer. Expert opinion on investigational drugs, 2008, Volume: 17, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Disease-Free Survival; Docetaxel; Humans; Male; Neoplasm Invasiveness; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Xanthones	2008

Trials

2 trial(s) available for docetaxel anhydrous and vadimezan

Article	Year
Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, May-15, Volume: 16, Issue:10 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Electrocardiography; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Xanthones	2010
The safety and tolerability of intravenous ASA404 when administered in combination with docetaxel (60 or 75 mg/m²) in Japanese patients with advanced or recurrent solid tumors. Japanese journal of clinical oncology, 2011, Volume: 41, Issue:9 Topics: Aged; Alopecia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Appetite; Asian People; Constipation; Docetaxel; Drug Administration Schedule; Fatigue; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Neutropenia; Severity of Illness Index; Taxoids; Treatment Outcome; Xanthones	2011

Article

Year

Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, May-15, Volume: 16, Issue:10

Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Electrocardiography; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Xanthones

2010

The safety and tolerability of intravenous ASA404 when administered in combination with docetaxel (60 or 75 mg/m²) in Japanese patients with advanced or recurrent solid tumors.

Japanese journal of clinical oncology, 2011, Volume: 41, Issue:9

Topics: Aged; Alopecia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Appetite; Asian People; Constipation; Docetaxel; Drug Administration Schedule; Fatigue; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Neutropenia; Severity of Illness Index; Taxoids; Treatment Outcome; Xanthones

2011